Medicina: Ematologia: Talassemie e trapianto del midollo osseo
| English |
| iron-chelation therapy |
  |
|
| Attestation |
3
|
| Part of speech |
Noun syntagm
|
| Grammatical label |
Countable
|
| Variant |
Chelation therapy, iron chelation treatment
|
| Definition |
Since 1977, long-term chelation therapy has been used to eliminate excess iron. This treatment, which consists of a slow (ie, overnight) subcutaneous injection of 1.5-2 g deferoxamine 5-6 times per week, creates a negative iron balance, which means that deferoxamine-induced iron excretion exceeds iron delivery by transfusion. Administration of high subcutaneous doses of deferoxamine to young children (before iron overload is established) is associated with a significant decrease in mean body length, joint stiffness, and a ricketslike syndrome.
|
| Definition source |
Lawson, JP. (2001). Thalassemia. E-Medicine. (INTEEN09)
|
| Context |
The most obvious benefits of BMT are freedom from the need for transfusion and in some, freedom from chelation therapy
|
| Context source |
Rund, D. & Rachmilevitz, E. (1995). ‘Thalassemia major 1995: older patients, new therapies’. Blood Reviews 9(1):25-32. Review. (RISCEN84)
|
| Subject field |
Haemopoiesis
|
| Sub-field (level 1) |
Thalassemias
|
| Sub-field (level 2) |
Therapies
|
| Coordinate concept |
Transfusional therapy, allogeneic bone marrow transplantation, syngeneic bone marrow transplantation, hematopoietic stem cell transplantation, gene therapy
|
| Related concept |
Chelation, iron overload, iron-chelating agent, desferrioxamine, deferiprone, HES-DFO, hemochromatosis, hemosiderosis, liver siderosis, transfusional therapy
|
| it |
Terapia ferrochelante
|
| Reliability code |
3
|
|
